Symbicort® (budesonide/formoterol fumarate dihydrate) – Expanded indication
January 30, 2017 – AstraZeneca announced the FDA approval of Symbicort (budesonide/formoterol fumarate dehydrate), for the treatment of asthma in patients 6 years of age and older.
Download PDF
